Anzeige
Mehr »
Montag, 26.01.2026 - Börsentäglich über 12.000 News
Gold über 5.000 USD verändert die Wirtschaftlichkeit grundlegend!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
17:46Internet of Medical Things beats AI as top ranked growth driver among life science CEOs
15:46UK biotechs suffered restricted financing in 2025
12:46MSD ends takeover talks with Revolution Medicines
12:46NICE greenlights Pfizer's Talzenna for NHS use
FrCorxel raises $287m as obesity continues to spark investor interest
FrDaiichi Sankyo and AstraZeneca's Enhertu gains NMPA approval for HER2 GEJ
DoBMS bets on Janux's novel solid tumour therapy through $850m deal
DoUS set to officially exit WHO in culmination of Trump's domestic push
DoHeart disease and stroke deaths take a downturn, AHA report reveals
DoJohnson & Johnson reports 9.1% increase in sales for Q4 2025
DoOpna Bio's OPN-2853 secures FDA's orphan drug status for myelofibrosis
MiDavos26: Trump says tariff threats helped fix US drug pricing 'unfairness'
MiPfizer and Novavax ink $530m vaccine delivery licensing deal
MiBMS and Microsoft partner for AI-based lung cancer detection
MiNovo Nordisk and Aspect Biosystems advance partnership for diabetes therapies
DiShionogi expands ViiV Healthcare stake by $2.13bn as Pfizer sells up
DiGSK scoops up RAPT Therapeutics for $2.2bn
DiDeepHow introduces PharmaCloud for pharmaceutical manufacturers
DiiRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson's
19.01.UK's pharma outlook buoyed by trans-Atlantic trade policies
19.01.Compounder sues Lilly and Novo for suppressing GLP-1RA competition
19.01.AstraZeneca to acquire China rights for AbelZeta's CAR-T therapy
19.01.FDA grants Novartis' ianalumab breakthrough therapy status for Sjögren's disease
16.01.FDA prevails over EMA in 2025 novel drug approvals
16.01.J&J's Caplyta doubles remission rate in MDD patients